|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:benefits
|
improves glycemic control
promotes weight loss
reduces cardiovascular risk
|
|
gptkbp:brand
|
gptkb:Jardiance
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
Phase III
adjunct to diet and exercise
EMPA-REGOUTCOME
EMPA-REG H2 H-SU
EMPA-REGBP
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to empagliflozin
|
|
gptkbp:dosage_form
|
gptkb:tablet
10 mg
25 mg
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Jardiance
|
|
gptkbp:ingredients
|
C23 H27 Cl O7 S
empagliflozin
|
|
gptkbp:interacts_with
|
gptkb:Company
diuretics
sulfonylureas
|
|
gptkbp:invention
|
2024
|
|
gptkbp:is_atype_of
|
A10 B K03
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:lifespan
|
12.4 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:2014
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
bioavailability 78%
inhibits SGL T2
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:products
|
gptkb:Invokana
gptkb:Farxiga
Steglatro
|
|
gptkbp:requires
|
available online
|
|
gptkbp:safety_features
|
risk of bone fractures
risk of ketoacidosis
risk of acute kidney injury
risk of dehydration
|
|
gptkbp:side_effect
|
dehydration
hypoglycemia
urinary tract infection
genital mycotic infection
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:bfsParent
|
gptkb:Farxiga
|
|
gptkbp:bfsLayer
|
4
|